AllianceBernstein’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

AllianceBernstein’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-492,190	Closed	-$48M	–	3520
2015 Q1	$48M	Sell	492,190 -58,622	-11%	-$6.21M	0.04%	494
2014 Q4	$51.1M	Sell	550,812 -33,597	-6%	-$2.65M	0.04%	460
2014 Q3	$40.2M	Buy	584,409 +40,493	+7%	+$2.9M	0.03%	519
2014 Q2	$57M	Buy	543,916 +8,005	+1%	+$681K	0.05%	429
2014 Q1	$44.5M	Buy	535,911 +192,046	+56%	+$17.8M	0.04%	490
2013 Q4	$22.3M	Sell	343,865 -57,508	-14%	-$3.41M	0.02%	639
2013 Q3	$25.4M	Sell	401,373 -40,685	-9%	-$2M	0.03%	593
2013 Q2	$18.6M	Buy	+442,058	New	+$20.1M	0.02%	656

AllianceBernstein's GEVA Position: Q2 2015 in Review

AllianceBernstein sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 492,190 shares — an estimated $48M sold.

AllianceBernstein first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $57M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

AllianceBernstein reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
AllianceBernstein sold 492,190 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $48M.
AllianceBernstein first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
AllianceBernstein's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $57M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on AllianceBernstein's 13F filing for Q2 2015, filed 14 Aug 2015.